Header Logo

Connection

JOSEPH JANKOVIC to Female

Back to Details
This is a "connection" page, showing publications JOSEPH JANKOVIC has written about Female.
JOSEPH JANKOVIC
Connection Strength
3.089
Female
  1. Axial tics in Tourette syndrome and chronic tic disorders. J Neurol. 2024 Nov; 271(11):7232-7238.
    View in: PubMed
    Score: 0.036
  2. Treatment response to onabotulinumtoxinA in cervical dystonia patients with anterocollis and retrocollis. Toxicon. 2024 Sep; 248:108035.
    View in: PubMed
    Score: 0.036
  3. Functional Neurological Disorders Among Patients With Tremor. J Neuropsychiatry Clin Neurosci. 2025; 37(1):61-66.
    View in: PubMed
    Score: 0.036
  4. Medication refractory restless legs syndrome: Real-world experience. J Neurol Sci. 2024 Aug 15; 463:123121.
    View in: PubMed
    Score: 0.036
  5. Leg stereotypy syndrome: phenomenological and quantitative analysis. J Neurol. 2024 Aug; 271(8):5519-5524.
    View in: PubMed
    Score: 0.036
  6. Contrasting features between Tourette syndrome and secondary tic disorders. J Neural Transm (Vienna). 2023 07; 130(7):931-936.
    View in: PubMed
    Score: 0.033
  7. Safety and Efficacy of Flexible-Dose Deutetrabenazine in Children and Adolescents With Tourette Syndrome: A Randomized Clinical Trial. JAMA Netw Open. 2021 10 01; 4(10):e2128204.
    View in: PubMed
    Score: 0.030
  8. Botulinum Neurotoxin Injections in Childhood Opisthotonus. Toxins (Basel). 2021 02 12; 13(2).
    View in: PubMed
    Score: 0.028
  9. Parkinson's disease after COVID-19. J Neurol Sci. 2021 03 15; 422:117331.
    View in: PubMed
    Score: 0.028
  10. Psychogenic (Functional) Movement Disorders. Continuum (Minneap Minn). 2019 Aug; 25(4):1121-1140.
    View in: PubMed
    Score: 0.025
  11. Young-onset Parkinson's disease: Its unique features and their impact on quality of life. Parkinsonism Relat Disord. 2019 08; 65:39-48.
    View in: PubMed
    Score: 0.025
  12. Clinical phenotype in carriers of intermediate alleles in the huntingtin gene. J Neurol Sci. 2019 Jul 15; 402:57-61.
    View in: PubMed
    Score: 0.025
  13. Real-World Experience With VMAT2 Inhibitors. Clin Neuropharmacol. 2019 Mar/Apr; 42(2):37-41.
    View in: PubMed
    Score: 0.025
  14. Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti-a-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease: A Randomized Clinical Trial. JAMA Neurol. 2018 10 01; 75(10):1206-1214.
    View in: PubMed
    Score: 0.024
  15. Botulinum Toxin for the Treatment of Hand Tremor. Toxins (Basel). 2018 07 19; 10(7).
    View in: PubMed
    Score: 0.024
  16. Cervical dystonia and substance abuse. J Neurol. 2018 Apr; 265(4):970-975.
    View in: PubMed
    Score: 0.023
  17. Onabotulinum toxin-A injections for sleep bruxism: A double-blind, placebo-controlled study. Neurology. 2018 02 13; 90(7):e559-e564.
    View in: PubMed
    Score: 0.023
  18. Leg stereotypy syndrome: phenomenology and prevalence. J Neurol Neurosurg Psychiatry. 2018 07; 89(7):692-695.
    View in: PubMed
    Score: 0.023
  19. Functional (psychogenic) stereotypies. J Neurol. 2017 Jul; 264(7):1482-1487.
    View in: PubMed
    Score: 0.022
  20. Apraclonidine in the treatment of ptosis. J Neurol Sci. 2017 May 15; 376:129-132.
    View in: PubMed
    Score: 0.022
  21. Examiner manoeuvres 'sensory tricks' in functional (psychogenic) movement disorders. J Neurol Neurosurg Psychiatry. 2017 05; 88(5):453-455.
    View in: PubMed
    Score: 0.021
  22. Distinguishing features of psychogenic (functional) versus organic hemifacial spasm. J Neurol. 2017 Feb; 264(2):359-363.
    View in: PubMed
    Score: 0.021
  23. Treatment of blepharospasm with apraclonidine. J Neurol Sci. 2017 Jan 15; 372:57-59.
    View in: PubMed
    Score: 0.021
  24. Neuropsychological outcomes from constant current deep brain stimulation for Parkinson's disease. Mov Disord. 2017 03; 32(3):433-440.
    View in: PubMed
    Score: 0.021
  25. Psychogenic Ophthalmologic Movement Disorders. J Neuropsychiatry Clin Neurosci. 2016; 28(3):195-8.
    View in: PubMed
    Score: 0.020
  26. Speech and voice disorders in patients with psychogenic movement disorders. J Neurol. 2015 Nov; 262(11):2420-4.
    View in: PubMed
    Score: 0.019
  27. Dopamine transporter imaging in essential tremor with and without parkinsonian features. J Neural Transm (Vienna). 2015 Nov; 122(11):1515-21.
    View in: PubMed
    Score: 0.019
  28. Bolivian kindred with combined spinocerebellar ataxia types 2 and 10. Acta Neurol Scand. 2015 Aug; 132(2):139-42.
    View in: PubMed
    Score: 0.019
  29. Primary results from the cervical dystonia patient registry for observation of onabotulinumtoxina efficacy (CD PROBE). J Neurol Sci. 2015 Feb 15; 349(1-2):84-93.
    View in: PubMed
    Score: 0.019
  30. Stiff-person syndrome: insights into a complex autoimmune disorder. J Neurol Neurosurg Psychiatry. 2015 Aug; 86(8):840-8.
    View in: PubMed
    Score: 0.018
  31. Randomized trial of IV valproate vs metoclopramide vs ketorolac for acute migraine. Neurology. 2014 Oct 07; 83(15):1388-9.
    View in: PubMed
    Score: 0.018
  32. Effects of long-term treatment with rotigotine transdermal system on dyskinesia in patients with early-stage Parkinson's disease. Parkinsonism Relat Disord. 2014 Dec; 20(12):1345-51.
    View in: PubMed
    Score: 0.018
  33. Symptomatic efficacy of rasagiline monotherapy in early Parkinson's disease: post-hoc analyses from the ADAGIO trial. Parkinsonism Relat Disord. 2014 Jun; 20(6):640-3.
    View in: PubMed
    Score: 0.018
  34. The clinical features of psychogenic movement disorders resembling tics. J Neurol Neurosurg Psychiatry. 2014 May; 85(5):573-5.
    View in: PubMed
    Score: 0.017
  35. Long-term efficacy and safety of fluphenazine in patients with Tourette syndrome. Mov Disord. 2014 Jan; 29(1):126-30.
    View in: PubMed
    Score: 0.017
  36. Flu-like symptoms and associated immunological response following therapy with botulinum toxins. Neurotox Res. 2013 Aug; 24(2):298-306.
    View in: PubMed
    Score: 0.017
  37. Zolpidem improves tardive dyskinesia and akathisia. Mov Disord. 2013 Oct; 28(12):1748-9.
    View in: PubMed
    Score: 0.017
  38. Bilateral globus pallidus internus deep brain stimulation after bilateral pallidotomy in a patient with generalized early-onset primary dystonia. Mov Disord. 2013 Jul; 28(8):1162-3.
    View in: PubMed
    Score: 0.016
  39. The VPS35 gene and Parkinson's disease. Mov Disord. 2013 May; 28(5):569-75.
    View in: PubMed
    Score: 0.016
  40. Analysis of CYP2D6 genotype and response to tetrabenazine. Mov Disord. 2013 Feb; 28(2):210-5.
    View in: PubMed
    Score: 0.016
  41. Respiratory disorders associated with dystonia. Mov Disord. 2012 Dec; 27(14):1816-9.
    View in: PubMed
    Score: 0.016
  42. Long-term safety and tolerability of rotigotine transdermal system in patients with early-stage idiopathic Parkinson's disease: a prospective, open-label extension study. Parkinsonism Relat Disord. 2012 Jun; 18(5):488-93.
    View in: PubMed
    Score: 0.015
  43. Rationale and design of a prospective study: Cervical Dystonia Patient Registry for Observation of OnaBotulinumtoxinA Efficacy (CD PROBE). BMC Neurol. 2011 Nov 04; 11:140.
    View in: PubMed
    Score: 0.015
  44. Convergence spasm in conversion disorders: prevalence in psychogenic and other movement disorders compared with controls. J Neurol Neurosurg Psychiatry. 2012 Feb; 83(2):202-4.
    View in: PubMed
    Score: 0.015
  45. The prevalence of symptomatic orthostatic hypotension in patients with Parkinson's disease and atypical parkinsonism. Parkinsonism Relat Disord. 2011 Sep; 17(8):625-8.
    View in: PubMed
    Score: 0.015
  46. Exploring the correlates of intermediate CAG repeats in Huntington disease. Postgrad Med. 2011 Sep; 123(5):116-21.
    View in: PubMed
    Score: 0.015
  47. Efficacy and safety of incobotulinumtoxinA (NT 201, Xeomin) in the treatment of blepharospasm-a randomized trial. Mov Disord. 2011 Jul; 26(8):1521-8.
    View in: PubMed
    Score: 0.014
  48. Parkinsonism and dystonia associated with adalimumab. Mov Disord. 2011 Jul; 26(8):1556-8.
    View in: PubMed
    Score: 0.014
  49. Transcutaneous electrical stimulation (TENS) for psychogenic movement disorders. J Neuropsychiatry Clin Neurosci. 2011; 23(2):141-8.
    View in: PubMed
    Score: 0.014
  50. Asian over-representation among patients with hemifacial spasm compared to patients with cranial-cervical dystonia. J Neurol Sci. 2010 Nov 15; 298(1-2):61-3.
    View in: PubMed
    Score: 0.014
  51. Tourette's syndrome in adults. Mov Disord. 2010 Oct 15; 25(13):2171-5.
    View in: PubMed
    Score: 0.014
  52. Correlation between Kinesia system assessments and clinical tremor scores in patients with essential tremor. Mov Disord. 2010 Sep 15; 25(12):1938-43.
    View in: PubMed
    Score: 0.014
  53. Psychogenic chorea associated with family history of Huntington disease. Mov Disord. 2010 Mar 15; 25(4):503-4.
    View in: PubMed
    Score: 0.013
  54. Examination of the MSX1 gene in patients with Parkinson's disease. Acta Neurol Scand. 2009 Dec; 120(6):442-4.
    View in: PubMed
    Score: 0.013
  55. Clinical efficacy and tolerability of Xeomin in the treatment of blepharospasm. Eur J Neurol. 2009 Dec; 16 Suppl 2:14-8.
    View in: PubMed
    Score: 0.013
  56. Relationship between neuropsychological outcome and DBS surgical trajectory and electrode location. J Neurol Sci. 2009 Dec 15; 287(1-2):159-71.
    View in: PubMed
    Score: 0.013
  57. Impact of STN-DBS on life and health satisfaction in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry. 2010 Mar; 81(3):315-9.
    View in: PubMed
    Score: 0.013
  58. A randomised, double-blind, placebo-controlled study of topiramate in the treatment of Tourette syndrome. J Neurol Neurosurg Psychiatry. 2010 Jan; 81(1):70-3.
    View in: PubMed
    Score: 0.013
  59. Efficacy and tolerability of pregabalin in essential tremor: a randomized, double-blind, placebo-controlled, crossover trial. J Neurol Sci. 2009 Oct 15; 285(1-2):195-7.
    View in: PubMed
    Score: 0.013
  60. Spinocerebellar ataxia 8: variable phenotype and unique pathogenesis. Parkinsonism Relat Disord. 2009 Nov; 15(9):621-6.
    View in: PubMed
    Score: 0.013
  61. Motor overflow and mirror dystonia. Parkinsonism Relat Disord. 2009 Dec; 15(10):758-61.
    View in: PubMed
    Score: 0.013
  62. Transcription factor PITX3 gene in Parkinson's disease. Neurobiol Aging. 2011 Apr; 32(4):750-3.
    View in: PubMed
    Score: 0.013
  63. Atomoxetine for freezing of gait in Parkinson disease. J Neurol Sci. 2009 Sep 15; 284(1-2):177-8.
    View in: PubMed
    Score: 0.012
  64. Hemidystonia-hemiatrophy syndrome. Mov Disord. 2009 Mar 15; 24(4):583-9.
    View in: PubMed
    Score: 0.012
  65. Acquired hepatocerebral degeneration. J Neurol. 2009 Mar; 256(3):320-32.
    View in: PubMed
    Score: 0.012
  66. Relationship between various clinical outcome assessments in patients with blepharospasm. Mov Disord. 2009 Feb 15; 24(3):407-13.
    View in: PubMed
    Score: 0.012
  67. Epidemiology and management of essential tremor in children. Paediatr Drugs. 2009; 11(5):293-307.
    View in: PubMed
    Score: 0.012
  68. Applause sign in Parkinsonian disorders and Huntington's disease. Mov Disord. 2008 Dec 15; 23(16):2307-11.
    View in: PubMed
    Score: 0.012
  69. Genetic study of an American family with DYT3 dystonia (lubag). Neurosci Lett. 2008 Dec 26; 448(2):180-3.
    View in: PubMed
    Score: 0.012
  70. Psychogenic movement disorders in children. Mov Disord. 2008 Oct 15; 23(13):1875-81.
    View in: PubMed
    Score: 0.012
  71. Decreased NURR1 gene expression in patients with Parkinson's disease. J Neurol Sci. 2008 Oct 15; 273(1-2):29-33.
    View in: PubMed
    Score: 0.012
  72. Shoulder pain: a presenting symptom of Parkinson disease. J Clin Rheumatol. 2008 Aug; 14(4):253-4.
    View in: PubMed
    Score: 0.012
  73. A study of chorea after tetrabenazine withdrawal in patients with Huntington disease. Clin Neuropharmacol. 2008 May-Jun; 31(3):127-33.
    View in: PubMed
    Score: 0.012
  74. Impulse control disorders and pathological gambling in patients with Parkinson disease. Neurologist. 2008 Mar; 14(2):89-99.
    View in: PubMed
    Score: 0.012
  75. Mutation analysis of the parkin and PINK1 genes in American Caucasian early-onset Parkinson disease families. Neurosci Lett. 2008 Jan 03; 430(1):18-22.
    View in: PubMed
    Score: 0.011
  76. Tardive gait. Clin Neurol Neurosurg. 2008 Feb; 110(2):198-201.
    View in: PubMed
    Score: 0.011
  77. Cognitive declines following bilateral subthalamic nucleus deep brain stimulation for the treatment of Parkinson's disease. J Neurol Neurosurg Psychiatry. 2008 Jul; 79(7):789-95.
    View in: PubMed
    Score: 0.011
  78. Hemiparkinsonism-hemiatrophy syndrome. Neurology. 2007 Oct 16; 69(16):1585-94.
    View in: PubMed
    Score: 0.011
  79. Focal hand dystonia, mirror dystonia and motor overflow. J Neurol Sci. 2008 Mar 15; 266(1-2):31-3.
    View in: PubMed
    Score: 0.011
  80. Malignant Tourette syndrome. Mov Disord. 2007 Sep 15; 22(12):1743-50.
    View in: PubMed
    Score: 0.011
  81. Overnight switch from oral dopaminergic agonists to transdermal rotigotine patch in subjects with Parkinson disease. Clin Neuropharmacol. 2007 Sep-Oct; 30(5):256-65.
    View in: PubMed
    Score: 0.011
  82. The other Babinski sign in hemifacial spasm. Neurology. 2007 Jul 24; 69(4):402-4.
    View in: PubMed
    Score: 0.011
  83. Distinguishing psychogenic and essential tremor. J Neurol Sci. 2007 Dec 15; 263(1-2):94-9.
    View in: PubMed
    Score: 0.011
  84. The effects of subthalamic nucleus deep brain stimulation on parkinsonian tremor. J Neurol Sci. 2007 Sep 15; 260(1-2):199-203.
    View in: PubMed
    Score: 0.011
  85. Transdermal rotigotine: double-blind, placebo-controlled trial in Parkinson disease. Arch Neurol. 2007 May; 64(5):676-82.
    View in: PubMed
    Score: 0.011
  86. Genetic analysis of LRRK2 P755L variant in Caucasian patients with Parkinson's disease. Neurosci Lett. 2007 May 29; 419(2):104-7.
    View in: PubMed
    Score: 0.011
  87. Prevalence of cervical dystonia and spasmodic torticollis in the United States general population. Parkinsonism Relat Disord. 2007 Oct; 13(7):411-6.
    View in: PubMed
    Score: 0.011
  88. Short-term and long-term safety of deep brain stimulation in the treatment of movement disorders. J Neurosurg. 2007 Apr; 106(4):621-5.
    View in: PubMed
    Score: 0.011
  89. Genetics of essential tremor. Brain. 2007 Jun; 130(Pt 6):1456-64.
    View in: PubMed
    Score: 0.011
  90. A family with Parkinson disease, essential tremor, bell palsy, and parkin mutations. Arch Neurol. 2007 Mar; 64(3):421-4.
    View in: PubMed
    Score: 0.011
  91. Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders. Mov Disord. 2007 Jan 15; 22(2):193-7.
    View in: PubMed
    Score: 0.011
  92. Short-term effects of tetrabenazine on chorea associated with Huntington's disease. Mov Disord. 2007 Jan; 22(1):10-3.
    View in: PubMed
    Score: 0.011
  93. Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia. Neurology. 2006 Dec 26; 67(12):2233-5.
    View in: PubMed
    Score: 0.011
  94. Comparing knowledge and attitudes towards genetic testing in Parkinson's disease in an American and Asian population. J Neurol Sci. 2007 Jan 31; 252(2):113-20.
    View in: PubMed
    Score: 0.011
  95. Examination of the SLITRK1 gene in Caucasian patients with Tourette syndrome. Acta Neurol Scand. 2006 Dec; 114(6):400-2.
    View in: PubMed
    Score: 0.011
  96. Genetic analysis of LRRK2 mutations in patients with Parkinson disease. J Neurol Sci. 2006 Dec 21; 251(1-2):102-6.
    View in: PubMed
    Score: 0.011
  97. Runner's dystonia. J Neurol Sci. 2006 Dec 21; 251(1-2):73-6.
    View in: PubMed
    Score: 0.011
  98. Joint and skeletal deformities in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Mov Disord. 2006 Nov; 21(11):1856-63.
    View in: PubMed
    Score: 0.011
  99. Botulinum toxin injection for congenital muscular torticollis presenting in children and adults. Neurology. 2006 Sep 26; 67(6):1083-5.
    View in: PubMed
    Score: 0.010
  100. Botulinum toxin treatment of facial myoclonus in suspected Rasmussen encephalitis. Mov Disord. 2006 Sep; 21(9):1500-2.
    View in: PubMed
    Score: 0.010
  101. Is history of depression a contraindication to treatment with tetrabenazine? Clin Neuropharmacol. 2006 Sep-Oct; 29(5):259-64.
    View in: PubMed
    Score: 0.010
  102. The LRRK2 I2012T, G2019S and I2020T mutations are not common in patients with essential tremor. Neurosci Lett. 2006 Oct 23; 407(2):97-100.
    View in: PubMed
    Score: 0.010
  103. Exploring the relationship between essential tremor and Parkinson's disease. Parkinsonism Relat Disord. 2007 Mar; 13(2):67-76.
    View in: PubMed
    Score: 0.010
  104. Psychogenic tremor: long-term outcome. CNS Spectr. 2006 Jul; 11(7):501-8.
    View in: PubMed
    Score: 0.010
  105. A functional variant of the dopamine D3 receptor is associated with risk and age-at-onset of essential tremor. Proc Natl Acad Sci U S A. 2006 Jul 11; 103(28):10753-8.
    View in: PubMed
    Score: 0.010
  106. Long-term prognosis of patients with psychogenic movement disorders. Parkinsonism Relat Disord. 2006 Sep; 12(6):382-7.
    View in: PubMed
    Score: 0.010
  107. Globus pallidus deep brain stimulation in dystonia. Mov Disord. 2006 May; 21(5):692-5.
    View in: PubMed
    Score: 0.010
  108. Gene dosage analysis of alpha-synuclein (SNCA) in patients with Parkinson's disease. Mov Disord. 2006 May; 21(5):728-9.
    View in: PubMed
    Score: 0.010
  109. Long-term evaluation of deep brain stimulation of the thalamus. J Neurosurg. 2006 Apr; 104(4):506-12.
    View in: PubMed
    Score: 0.010
  110. Genetic analysis of the GABRA1 gene in patients with essential tremor. Neurosci Lett. 2006 Jun 19; 401(1-2):16-9.
    View in: PubMed
    Score: 0.010
  111. Heterogeneous phenotype in a family with compound heterozygous parkin gene mutations. Arch Neurol. 2006 Feb; 63(2):273-7.
    View in: PubMed
    Score: 0.010
  112. Tourette's syndrome and the law. J Neuropsychiatry Clin Neurosci. 2006; 18(1):86-95.
    View in: PubMed
    Score: 0.010
  113. Modafinil for daytime somnolence in Parkinson's disease: double blind, placebo controlled parallel trial. J Neurol Neurosurg Psychiatry. 2005 Dec; 76(12):1636-9.
    View in: PubMed
    Score: 0.010
  114. Autonomic function after botulinum toxin type A or B: a double-blind, randomized trial. Neurology. 2005 Sep 13; 65(5):765-7.
    View in: PubMed
    Score: 0.010
  115. Palatal myoclonus: an unusual presentation. Mov Disord. 2005 Sep; 20(9):1200-3.
    View in: PubMed
    Score: 0.010
  116. Extended study of A265G variant of HS1BP3 in essential tremor and Parkinson disease. Neurology. 2005 Aug 23; 65(4):651-2.
    View in: PubMed
    Score: 0.010
  117. Camptocormia: pathogenesis, classification, and response to therapy. Neurology. 2005 Aug 09; 65(3):355-9.
    View in: PubMed
    Score: 0.010
  118. G309D and W437OPA PINK1 mutations in Caucasian Parkinson's disease patients. Acta Neurol Scand. 2005 Jun; 111(6):351-2.
    View in: PubMed
    Score: 0.010
  119. Genetic and clinical identification of Parkinson's disease patients with LRRK2 G2019S mutation. Ann Neurol. 2005 Jun; 57(6):933-4.
    View in: PubMed
    Score: 0.010
  120. Long-term botulinum toxin efficacy, safety, and immunogenicity. Mov Disord. 2005 May; 20(5):592-7.
    View in: PubMed
    Score: 0.009
  121. Secondary tics and tourettism. Braz J Psychiatry. 2005 Mar; 27(1):11-7.
    View in: PubMed
    Score: 0.009
  122. Genetic analysis of parkin co-regulated gene (PACRG) in patients with early-onset parkinsonism. Neurosci Lett. 2005 Jul 15; 382(3):297-9.
    View in: PubMed
    Score: 0.009
  123. Metoclopramide-induced tardive dyskinesia in an infant. Mov Disord. 2005 Jan; 20(1):86-9.
    View in: PubMed
    Score: 0.009
  124. Motor fluctuations and dyskinesias in Parkinson's disease: clinical manifestations. Mov Disord. 2005; 20 Suppl 11:S11-6.
    View in: PubMed
    Score: 0.009
  125. Factor analysis and clustering of motor and psychiatric dimensions in idiopathic blepharospasm. Parkinsonism Relat Disord. 2025 Feb; 131:107241.
    View in: PubMed
    Score: 0.009
  126. Essential tremor among children. Pediatrics. 2004 Nov; 114(5):1203-5.
    View in: PubMed
    Score: 0.009
  127. An open-label pilot study of levetiracetam for essential tremor. Clin Neuropharmacol. 2004 Nov-Dec; 27(6):274-7.
    View in: PubMed
    Score: 0.009
  128. Glabellar and palmomental reflexes in Parkinsonian disorders. Neurology. 2004 Sep 28; 63(6):1096-8.
    View in: PubMed
    Score: 0.009
  129. Minocycline in Huntington's disease: a pilot study. Mov Disord. 2004 Jun; 19(6):692-5.
    View in: PubMed
    Score: 0.009
  130. Basal ganglia neuronal discharge in primary and secondary dystonia. Adv Neurol. 2004; 94:29-36.
    View in: PubMed
    Score: 0.009
  131. Clinical heterogeneity of neurodegeneration with brain iron accumulation (Hallervorden-Spatz syndrome) and pantothenate kinase-associated neurodegeneration. Mov Disord. 2004 Jan; 19(1):36-42.
    View in: PubMed
    Score: 0.009
  132. Premonitory sensory phenomenon in Tourette's syndrome. Mov Disord. 2003 Dec; 18(12):1530-3.
    View in: PubMed
    Score: 0.009
  133. Migraine headache in patients with Tourette syndrome. Arch Neurol. 2003 Nov; 60(11):1595-8.
    View in: PubMed
    Score: 0.009
  134. Hearing impairment in essential tremor. Neurology. 2003 Oct 28; 61(8):1093-7.
    View in: PubMed
    Score: 0.009
  135. Basal ganglia neuronal discharge in primary and secondary dystonia in patients undergoing pallidotomy. Neurosurgery. 2003 Jun; 52(6):1358-70; discussion 1370-3.
    View in: PubMed
    Score: 0.008
  136. Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia. Neurology. 2003 Apr 08; 60(7):1186-8.
    View in: PubMed
    Score: 0.008
  137. COVID19-associated new-onset movement disorders: a follow-up study. J Neurol. 2023 May; 270(5):2409-2415.
    View in: PubMed
    Score: 0.008
  138. Soleus H-reflex measures in patients with focal and generalized dystonia. Clin Neurophysiol. 2003 Feb; 114(2):288-94.
    View in: PubMed
    Score: 0.008
  139. Movement disorders in Friedreich's ataxia. J Neurol Sci. 2003 Jan 15; 206(1):59-64.
    View in: PubMed
    Score: 0.008
  140. Tetrabenazine treatment for Huntington's disease-associated chorea. Clin Neuropharmacol. 2002 Nov-Dec; 25(6):300-2.
    View in: PubMed
    Score: 0.008
  141. Olanzapine treatment for dopaminergic-induced hallucinations. Mov Disord. 2002 Sep; 17(5):1031-5.
    View in: PubMed
    Score: 0.008
  142. Secondary paroxysmal dyskinesias. Mov Disord. 2002 Jul; 17(4):726-34.
    View in: PubMed
    Score: 0.008
  143. H-reflex recovery curves differentiate essential tremor, Parkinson's disease, and the combination of essential tremor and Parkinson's disease. J Clin Neurophysiol. 2002 Jun; 19(3):245-51.
    View in: PubMed
    Score: 0.008
  144. Exploring the relationship between Parkinson disease and restless legs syndrome. Arch Neurol. 2002 Mar; 59(3):421-4.
    View in: PubMed
    Score: 0.008
  145. A double-blind, placebo-controlled and longitudinal study of riluzole in early Parkinson's disease. Parkinsonism Relat Disord. 2002 Mar; 8(4):271-6.
    View in: PubMed
    Score: 0.008
  146. Association of Essential Tremor With Novel Risk Loci: A Genome-Wide Association Study and Meta-analysis. JAMA Neurol. 2022 02 01; 79(2):185-193.
    View in: PubMed
    Score: 0.008
  147. Methods of H-reflex evaluation in the early stages of Parkinson's disease. J Clin Neurophysiol. 2002 Jan; 19(1):67-72.
    View in: PubMed
    Score: 0.008
  148. Secondary causes of paroxysmal dyskinesia. Adv Neurol. 2002; 89:401-20.
    View in: PubMed
    Score: 0.008
  149. Daytime sleepiness and other sleep disorders in Parkinson's disease. Neurology. 2001 Oct 23; 57(8):1392-6.
    View in: PubMed
    Score: 0.007
  150. Efficacy and Safety of Fixed-Dose Deutetrabenazine in Children and Adolescents for Tics Associated With Tourette Syndrome: A Randomized Clinical Trial. JAMA Netw Open. 2021 10 01; 4(10):e2129397.
    View in: PubMed
    Score: 0.007
  151. Diagnostic criteria for blepharospasm: A multicenter international study. Parkinsonism Relat Disord. 2021 10; 91:109-114.
    View in: PubMed
    Score: 0.007
  152. Clinical-Instrumental patterns of neurodegeneration in Essential Tremor: A data-driven approach. Parkinsonism Relat Disord. 2021 06; 87:124-129.
    View in: PubMed
    Score: 0.007
  153. Concepts and methods in chronic thalamic stimulation for treatment of tremor: technique and application. Neurosurgery. 2001 Mar; 48(3):535-41; discussion 541-3.
    View in: PubMed
    Score: 0.007
  154. Dystonia in corticobasal degeneration. Mov Disord. 2001 Mar; 16(2):252-7.
    View in: PubMed
    Score: 0.007
  155. Quantitative mobility measures complement the MDS-UPDRS for characterization of Parkinson's disease heterogeneity. Parkinsonism Relat Disord. 2021 03; 84:105-111.
    View in: PubMed
    Score: 0.007
  156. Re-emergence of childhood stuttering in Parkinson's disease: a hypothesis. Mov Disord. 2001 Jan; 16(1):114-8.
    View in: PubMed
    Score: 0.007
  157. Switching from pergolide to pramipexole in patients with Parkinson's disease. J Neural Transm (Vienna). 2001; 108(1):63-70.
    View in: PubMed
    Score: 0.007
  158. Effects of pallidotomy on gait and balance. Adv Neurol. 2001; 87:271-81.
    View in: PubMed
    Score: 0.007
  159. Psychogenic hemifacial spasm. J Neuropsychiatry Clin Neurosci. 2001; 13(3):380-4.
    View in: PubMed
    Score: 0.007
  160. Dystonia and Tremor: A Cross-Sectional Study of the Dystonia Coalition Cohort. Neurology. 2021 01 26; 96(4):e563-e574.
    View in: PubMed
    Score: 0.007
  161. Computerized posturography analysis of progressive supranuclear palsy: a case-control comparison with Parkinson's disease and healthy controls. Arch Neurol. 2000 Oct; 57(10):1464-9.
    View in: PubMed
    Score: 0.007
  162. Clinical and Demographic Characteristics of Upper Limb Dystonia. Mov Disord. 2020 11; 35(11):2086-2090.
    View in: PubMed
    Score: 0.007
  163. Botulinum toxin in the treatment of tics. Arch Neurol. 2000 Aug; 57(8):1190-3.
    View in: PubMed
    Score: 0.007
  164. Understanding the relationship between freezing of gait and other progressive supranuclear palsy features. Parkinsonism Relat Disord. 2020 09; 78:56-60.
    View in: PubMed
    Score: 0.007
  165. Gabapentin for essential tremor: a multiple-dose, double-blind, placebo-controlled trial. Mov Disord. 2000 Jul; 15(4):678-82.
    View in: PubMed
    Score: 0.007
  166. The evolution of diagnosis in early Parkinson disease. Parkinson Study Group. Arch Neurol. 2000 Mar; 57(3):369-72.
    View in: PubMed
    Score: 0.007
  167. Tardive and idiopathic oromandibular dystonia: a clinical comparison. J Neurol Neurosurg Psychiatry. 2000 Feb; 68(2):186-90.
    View in: PubMed
    Score: 0.007
  168. Treating severe bruxism with botulinum toxin. J Am Dent Assoc. 2000 Feb; 131(2):211-6.
    View in: PubMed
    Score: 0.007
  169. Postural Directionality and Head Tremor in Cervical Dystonia. Tremor Other Hyperkinet Mov (N Y). 2020; 10.
    View in: PubMed
    Score: 0.007
  170. Essential tremor: clinical characteristics. Neurology. 2000; 54(11 Suppl 4):S21-5.
    View in: PubMed
    Score: 0.007
  171. EASE LID 2: A 2-Year Open-Label Trial of Gocovri (Amantadine) Extended Release for Dyskinesia in Parkinson's Disease. J Parkinsons Dis. 2020; 10(2):543-558.
    View in: PubMed
    Score: 0.007
  172. Functional gait disorders, clinical phenomenology, and classification. Neurol Sci. 2020 Apr; 41(4):911-915.
    View in: PubMed
    Score: 0.007
  173. Botulinum toxin A in patients with oromandibular dystonia: long-term follow-up. Neurology. 1999 Dec 10; 53(9):2102-7.
    View in: PubMed
    Score: 0.007
  174. Re-emergent tremor of Parkinson's disease. J Neurol Neurosurg Psychiatry. 1999 Nov; 67(5):646-50.
    View in: PubMed
    Score: 0.006
  175. Bilineal transmission in Tourette syndrome. Neurology. 1999 Sep 11; 53(4):813-8.
    View in: PubMed
    Score: 0.006
  176. Hypertension and progressive supranuclear palsy. Parkinsonism Relat Disord. 2019 09; 66:166-170.
    View in: PubMed
    Score: 0.006
  177. Tetrabenazine treatment for tardive dyskinesia: assessment by randomized videotape protocol. Am J Psychiatry. 1999 Aug; 156(8):1279-81.
    View in: PubMed
    Score: 0.006
  178. Levodopa-induced dyskinesias treated by pallidotomy. J Neurol Sci. 1999 Aug 01; 167(1):62-7.
    View in: PubMed
    Score: 0.006
  179. Minimal clinically important change in patients with cervical dystonia: Results from the CD PROBE study. J Neurol Sci. 2019 Oct 15; 405:116413.
    View in: PubMed
    Score: 0.006
  180. A novel sublingual apomorphine treatment for patients with fluctuating Parkinson's disease. Mov Disord. 1999 Jul; 14(4):664-8.
    View in: PubMed
    Score: 0.006
  181. Bruxism and cranial-cervical dystonia: is there a relationship? Cranio. 1999 Jul; 17(3):196-201.
    View in: PubMed
    Score: 0.006
  182. Exercise performance in those having Parkinson's disease and healthy normals. Med Sci Sports Exerc. 1999 Jun; 31(6):761-6.
    View in: PubMed
    Score: 0.006
  183. Autosomal dominant mitochondrial membrane protein-associated neurodegeneration (MPAN). Mol Genet Genomic Med. 2019 07; 7(7):e00736.
    View in: PubMed
    Score: 0.006
  184. Head tremor at disease onset: an ataxic phenotype of cervical dystonia. J Neurol. 2019 Aug; 266(8):1844-1851.
    View in: PubMed
    Score: 0.006
  185. Parkinson's disease age at onset genome-wide association study: Defining heritability, genetic loci, and a-synuclein mechanisms. Mov Disord. 2019 06; 34(6):866-875.
    View in: PubMed
    Score: 0.006
  186. Bilateral hemifacial spasm: a report of five cases and a literature review. Mov Disord. 1999 Mar; 14(2):345-9.
    View in: PubMed
    Score: 0.006
  187. Movement and reaction times and fine coordination tasks following pallidotomy. Mov Disord. 1999 Jan; 14(1):57-62.
    View in: PubMed
    Score: 0.006
  188. Clinical correlates of vascular parkinsonism. Arch Neurol. 1999 Jan; 56(1):98-102.
    View in: PubMed
    Score: 0.006
  189. Efficacy and tolerability of a novel sublingual apomorphine preparation in patients with fluctuating Parkinson's disease. Clin Neuropharmacol. 1999 Jan-Feb; 22(1):1-4.
    View in: PubMed
    Score: 0.006
  190. Attitudes toward neurosurgical procedures for Parkinson's disease and obsessive-compulsive disorder. J Neuropsychiatry Clin Neurosci. 1999; 11(2):259-67.
    View in: PubMed
    Score: 0.006
  191. Hemifacial spasm: clinical findings and treatment. Muscle Nerve. 1998 Dec; 21(12):1740-7.
    View in: PubMed
    Score: 0.006
  192. Peripherally induced oromandibular dystonia. J Neurol Neurosurg Psychiatry. 1998 Nov; 65(5):722-8.
    View in: PubMed
    Score: 0.006
  193. Predictors of alcohol responsiveness in dystonia. Neurology. 2018 11 20; 91(21):e2020-e2026.
    View in: PubMed
    Score: 0.006
  194. Ecopipam, a D1 receptor antagonist, for treatment of tourette syndrome in children: A randomized, placebo-controlled crossover study. Mov Disord. 2018 08; 33(8):1272-1280.
    View in: PubMed
    Score: 0.006
  195. Benefits and risks of unilateral and bilateral ventral intermediate nucleus deep brain stimulation for axial essential tremor symptoms. Parkinsonism Relat Disord. 2019 03; 60:126-132.
    View in: PubMed
    Score: 0.006
  196. Local field potentials of subthalamic nucleus contain electrophysiological footprints of motor subtypes of Parkinson's disease. Proc Natl Acad Sci U S A. 2018 09 04; 115(36):E8567-E8576.
    View in: PubMed
    Score: 0.006
  197. Consensus for the measurement of the camptocormia angle in the standing patient. Parkinsonism Relat Disord. 2018 07; 52:1-5.
    View in: PubMed
    Score: 0.006
  198. Mouse bioassay versus Western blot assay for botulinum toxin antibodies: correlation with clinical response. Neurology. 1998 Jun; 50(6):1624-9.
    View in: PubMed
    Score: 0.006
  199. Post-traumatic movement disorders: effect of the legal system on outcome. J Forensic Sci. 1998 Mar; 43(2):334-9.
    View in: PubMed
    Score: 0.006
  200. Lifetime exposure to estrogen and progressive supranuclear palsy: Environmental and Genetic PSP study. Mov Disord. 2018 03; 33(3):468-472.
    View in: PubMed
    Score: 0.006
  201. Excessive burden of lysosomal storage disorder gene variants in Parkinson's disease. Brain. 2017 12 01; 140(12):3191-3203.
    View in: PubMed
    Score: 0.006
  202. The Regions on the Light Chain of Botulinum Neurotoxin Type A Recognized by T Cells from Toxin-Treated Cervical Dystonia Patients. The Complete Human T-Cell Recognition Map of the Toxin Molecule. Immunol Invest. 2018 Jan; 47(1):18-39.
    View in: PubMed
    Score: 0.006
  203. Safety of Converting From Tetrabenazine to Deutetrabenazine for the Treatment of Chorea. JAMA Neurol. 2017 08 01; 74(8):977-982.
    View in: PubMed
    Score: 0.006
  204. ADCY5-related movement disorders: Frequency, disease course and phenotypic variability in a cohort of paediatric patients. Parkinsonism Relat Disord. 2017 Aug; 41:37-43.
    View in: PubMed
    Score: 0.005
  205. Psychiatric associations of adult-onset focal dystonia phenotypes. J Neurol Neurosurg Psychiatry. 2017 07; 88(7):595-602.
    View in: PubMed
    Score: 0.005
  206. Thalamic DBS with a constant-current device in essential tremor: A?controlled clinical trial. Parkinsonism Relat Disord. 2017 Jul; 40:18-26.
    View in: PubMed
    Score: 0.005
  207. Familial essential tremor in 4 kindreds. Prospects for genetic mapping. Arch Neurol. 1997 Mar; 54(3):289-94.
    View in: PubMed
    Score: 0.005
  208. Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology. 1997 Feb; 48(2):358-62.
    View in: PubMed
    Score: 0.005
  209. Assessment of Safety and Efficacy of Safinamide as a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial. JAMA Neurol. 2017 Feb 01; 74(2):216-224.
    View in: PubMed
    Score: 0.005
  210. Improvement of parkinsonian signs after vascular lesions of the basal ganglia circuitry. Mov Disord. 1997 Jan; 12(1):124-6.
    View in: PubMed
    Score: 0.005
  211. Thalamic surgery for movement disorders. Adv Neurol. 1997; 74:221-33.
    View in: PubMed
    Score: 0.005
  212. Understanding falls in progressive supranuclear palsy. Parkinsonism Relat Disord. 2017 02; 35:75-81.
    View in: PubMed
    Score: 0.005
  213. A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease. Neurology. 2017 Jan 10; 88(2):152-159.
    View in: PubMed
    Score: 0.005
  214. Restless legs syndrome: clinicoetiologic correlates. Neurology. 1996 Dec; 47(6):1435-41.
    View in: PubMed
    Score: 0.005
  215. Submolecular recognition regions of the HN domain of the heavy chain of botulinum neurotoxin type A by T cells from toxin-treated cervical dystonia patients. J Neuroimmunol. 2016 11 15; 300:36-46.
    View in: PubMed
    Score: 0.005
  216. Propofol-induced dyskinesias in Parkinson's disease. Anesth Analg. 1996 Aug; 83(2):420-22.
    View in: PubMed
    Score: 0.005
  217. Effect of Deutetrabenazine on Chorea Among Patients With Huntington Disease: A Randomized Clinical Trial. JAMA. 2016 Jul 05; 316(1):40-50.
    View in: PubMed
    Score: 0.005
  218. Identification of TMEM230 mutations in familial Parkinson's disease. Nat Genet. 2016 07; 48(7):733-9.
    View in: PubMed
    Score: 0.005
  219. A randomized, double-blind, placebo-controlled study to evaluate botulinum toxin type A in essential hand tremor. Mov Disord. 1996 May; 11(3):250-6.
    View in: PubMed
    Score: 0.005
  220. Clinimetric testing of the comprehensive cervical dystonia rating scale. Mov Disord. 2016 Apr; 31(4):563-9.
    View in: PubMed
    Score: 0.005
  221. Delayed-onset progressive movement disorders after static brain lesions. Neurology. 1996 Jan; 46(1):68-74.
    View in: PubMed
    Score: 0.005
  222. Clinical-Genetic Associations in the Prospective Huntington at Risk Observational Study (PHAROS): Implications for Clinical Trials. JAMA Neurol. 2016 Jan; 73(1):102-10.
    View in: PubMed
    Score: 0.005
  223. Whole-Exome Sequencing in Familial Parkinson Disease. JAMA Neurol. 2016 Jan; 73(1):68-75.
    View in: PubMed
    Score: 0.005
  224. Submolecular recognition of the C-terminal domain of the heavy chain of botulinum neurotoxin type A by T cells from toxin-treated cervical dystonia patients. Immunobiology. 2016 Apr; 221(4):568-76.
    View in: PubMed
    Score: 0.005
  225. Movement Disorders From the Use of Metoclopramide and Other Antiemetics in the Treatment of Migraine. Headache. 2016 Jan; 56(1):153-61.
    View in: PubMed
    Score: 0.005
  226. Paroxysmal dyskinesias: clinical features and classification. Ann Neurol. 1995 Oct; 38(4):571-9.
    View in: PubMed
    Score: 0.005
  227. Outcome after stereotactic thalamotomy for parkinsonian, essential, and other types of tremor. Neurosurgery. 1995 Oct; 37(4):680-6; discussion 686-7.
    View in: PubMed
    Score: 0.005
  228. Response and immunoresistance to botulinum toxin injections. Neurology. 1995 Sep; 45(9):1743-6.
    View in: PubMed
    Score: 0.005
  229. Diffusion imaging of nigral alterations in early Parkinson's disease with dopaminergic deficits. Mov Disord. 2015 Dec; 30(14):1885-92.
    View in: PubMed
    Score: 0.005
  230. Emotional and functional impact of DNA testing on patients with symptoms of Huntington's disease. J Med Genet. 1995 Jul; 32(7):516-8.
    View in: PubMed
    Score: 0.005
  231. Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: A double-blind, randomized, controlled trial. Ann Neurol. 2015 Aug; 78(2):248-57.
    View in: PubMed
    Score: 0.005
  232. A Pilot Study of a Cognitive-Behavioral Treatment for Anxiety and Depression in Patients With Parkinson Disease. J Geriatr Psychiatry Neurol. 2015 Sep; 28(3):210-7.
    View in: PubMed
    Score: 0.005
  233. Natural history of multiple system atrophy in the USA: a prospective cohort study. Lancet Neurol. 2015 Jul; 14(7):710-9.
    View in: PubMed
    Score: 0.005
  234. Tremor and longevity in relatives of patients with Parkinson's disease, essential tremor, and control subjects. Neurology. 1995 Apr; 45(4):645-8.
    View in: PubMed
    Score: 0.005
  235. Peripherally induced tremor and parkinsonism. Arch Neurol. 1995 Mar; 52(3):263-70.
    View in: PubMed
    Score: 0.005
  236. Epigenetic mechanisms in Parkinson's disease. J Neurol Sci. 2015 Feb 15; 349(1-2):3-9.
    View in: PubMed
    Score: 0.005
  237. Post-traumatic movement disorders: central and peripheral mechanisms. Neurology. 1994 Nov; 44(11):2006-14.
    View in: PubMed
    Score: 0.005
  238. Cross-disorder genome-wide analyses suggest a complex genetic relationship between Tourette's syndrome and OCD. Am J Psychiatry. 2015 Jan; 172(1):82-93.
    View in: PubMed
    Score: 0.005
  239. IncobotulinumtoxinA (Xeomin?) injected for blepharospasm or cervical dystonia according to patient needs is well tolerated. J Neurol Sci. 2014 Nov 15; 346(1-2):116-20.
    View in: PubMed
    Score: 0.005
  240. Copy number variation in obsessive-compulsive disorder and tourette syndrome: a cross-disorder study. J Am Acad Child Adolesc Psychiatry. 2014 Aug; 53(8):910-9.
    View in: PubMed
    Score: 0.004
  241. Neurohistopathological findings at the electrode-tissue interface in long-term deep brain stimulation: systematic literature review, case report, and assessment of stimulation threshold safety. Neuromodulation. 2014 Jul; 17(5):405-18; discussion 418.
    View in: PubMed
    Score: 0.004
  242. CAG repeat size and clinical presentation in Huntington's disease. Neurology. 1994 Jun; 44(6):1137-43.
    View in: PubMed
    Score: 0.004
  243. Peptidoglycan recognition protein genes and risk of Parkinson's disease. Mov Disord. 2014 Aug; 29(9):1171-80.
    View in: PubMed
    Score: 0.004
  244. Alleviating manoeuvres (sensory tricks) in cervical dystonia. J Neurol Neurosurg Psychiatry. 2014 Aug; 85(8):882-4.
    View in: PubMed
    Score: 0.004
  245. Cervical dystonia and pain: characteristics and treatment patterns from CD PROBE (Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efficacy). J Neurol. 2014 Jul; 261(7):1309-19.
    View in: PubMed
    Score: 0.004
  246. Vascular progressive supranuclear palsy. J Neural Transm Suppl. 1994; 42:189-201.
    View in: PubMed
    Score: 0.004
  247. The safety and efficacy of thalamic deep brain stimulation in essential tremor: 10 years and beyond. J Neurol Neurosurg Psychiatry. 2014 May; 85(5):567-72.
    View in: PubMed
    Score: 0.004
  248. What is it? Case 1, 1993: parkinsonism, dysautonomia, and ophthalmoparesis. Mov Disord. 1993 Oct; 8(4):525-32.
    View in: PubMed
    Score: 0.004
  249. Randomized trial of IPX066, carbidopa/levodopa extended release, in early Parkinson's disease. Parkinsonism Relat Disord. 2014 Feb; 20(2):142-8.
    View in: PubMed
    Score: 0.004
  250. Use of botulinum toxin in the treatment of hand dystonia. J Hand Surg Am. 1993 Sep; 18(5):883-7.
    View in: PubMed
    Score: 0.004
  251. Neurogenic orthostatic hypotension: a double-blind, placebo-controlled study with midodrine. Am J Med. 1993 Jul; 95(1):38-48.
    View in: PubMed
    Score: 0.004
  252. Tardive stereotypy and other movement disorders in tardive dyskinesias. Neurology. 1993 May; 43(5):937-41.
    View in: PubMed
    Score: 0.004
  253. Longitudinal experience with botulinum toxin injections for treatment of blepharospasm and cervical dystonia. Neurology. 1993 Apr; 43(4):834-6.
    View in: PubMed
    Score: 0.004
  254. Cocaine-related movement disorders. Mov Disord. 1993 Apr; 8(2):175-8.
    View in: PubMed
    Score: 0.004
  255. Deprenyl in attention deficit associated with Tourette's syndrome. Arch Neurol. 1993 Mar; 50(3):286-8.
    View in: PubMed
    Score: 0.004
  256. Sustained efficacy and safety of repeated incobotulinumtoxinA (Xeomin(?)) injections in blepharospasm. J Neural Transm (Vienna). 2013 Sep; 120(9):1345-53.
    View in: PubMed
    Score: 0.004
  257. How to identify tremor dominant and postural instability/gait difficulty groups with the movement disorder society unified Parkinson's disease rating scale: comparison with the unified Parkinson's disease rating scale. Mov Disord. 2013 May; 28(5):668-70.
    View in: PubMed
    Score: 0.004
  258. The spectrum of movement disorders in children with anti-NMDA receptor encephalitis. Mov Disord. 2013 Apr; 28(4):543-7.
    View in: PubMed
    Score: 0.004
  259. Psychogenic myoclonus. Neurology. 1993 Feb; 43(2):349-52.
    View in: PubMed
    Score: 0.004
  260. Reliability of a new scale for essential tremor. Mov Disord. 2012 Oct; 27(12):1567-9.
    View in: PubMed
    Score: 0.004
  261. Globus pallidus deep brain stimulation for refractory idiopathic restless legs syndrome. Sleep Med. 2012 Oct; 13(9):1202-4.
    View in: PubMed
    Score: 0.004
  262. The alien hand and related signs. J Neurol Neurosurg Psychiatry. 1992 Sep; 55(9):806-10.
    View in: PubMed
    Score: 0.004
  263. Mutation screening of the HTR2B gene in patients with Tourette syndrome. Neurosci Lett. 2012 Sep 27; 526(2):150-3.
    View in: PubMed
    Score: 0.004
  264. Deep brain stimulation hardware complications in patients with movement disorders: risk factors and clinical correlations. Stereotact Funct Neurosurg. 2012; 90(5):300-6.
    View in: PubMed
    Score: 0.004
  265. Alternating verbal fluency performance following bilateral subthalamic nucleus deep brain stimulation for Parkinson's disease. Eur J Neurol. 2012 Dec; 19(12):1525-31.
    View in: PubMed
    Score: 0.004
  266. Low body weight in Parkinson's disease. South Med J. 1992 Apr; 85(4):351-4.
    View in: PubMed
    Score: 0.004
  267. Acoustic reflex abnormalities in cranial-cervical dystonia. Neurology. 1992 Mar; 42(3 Pt 1):594-7.
    View in: PubMed
    Score: 0.004
  268. Subthalamic deep brain stimulation with a constant-current device in Parkinson's disease: an open-label randomised controlled trial. Lancet Neurol. 2012 Feb; 11(2):140-9.
    View in: PubMed
    Score: 0.004
  269. Head injury, a-synuclein Rep1, and Parkinson's disease. Ann Neurol. 2012 Jan; 71(1):40-8.
    View in: PubMed
    Score: 0.004
  270. Tardive tremor. Mov Disord. 1992; 7(1):53-7.
    View in: PubMed
    Score: 0.004
  271. Mutations in the gene PRRT2 cause paroxysmal kinesigenic dyskinesia with infantile convulsions. Cell Rep. 2012 Jan 26; 1(1):2-12.
    View in: PubMed
    Score: 0.004
  272. Perampanel, an AMPA antagonist, found to have no benefit in reducing "off" time in Parkinson's disease. Mov Disord. 2012 Feb; 27(2):284-8.
    View in: PubMed
    Score: 0.004
  273. Clinical correlates of response to botulinum toxin injections. Arch Neurol. 1991 Dec; 48(12):1253-6.
    View in: PubMed
    Score: 0.004
  274. Human T-cell responses to botulinum neurotoxin. Responses in vitro of lymphocytes from patients with cervical dystonia and/or other movement disorders treated with BoNT/A or BoNT/B. J Neuroimmunol. 2011 Dec 15; 240-241:121-8.
    View in: PubMed
    Score: 0.004
  275. Reflexive and volitional saccades: biomarkers of Huntington disease severity and progression. J Neurol Sci. 2012 Feb 15; 313(1-2):35-41.
    View in: PubMed
    Score: 0.004
  276. The coexistence of tics and dystonia. Arch Neurol. 1991 Aug; 48(8):862-5.
    View in: PubMed
    Score: 0.004
  277. Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN?, botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia. J Neurol Sci. 2011 Sep 15; 308(1-2):103-9.
    View in: PubMed
    Score: 0.004
  278. Human T-cell responses to botulinum neurotoxin: proliferative responses in vitro of lymphocytes from botulinum neurotoxin A-treated movement disorder patients. J Neuroimmunol. 2011 Aug 15; 237(1-2):66-72.
    View in: PubMed
    Score: 0.004
  279. Cervical dystonia: clinical findings and associated movement disorders. Neurology. 1991 Jul; 41(7):1088-91.
    View in: PubMed
    Score: 0.004
  280. Changes in cognitive-emotional and physiological symptoms of depression following STN-DBS for the treatment of Parkinson's disease. Eur J Neurol. 2012 Jan; 19(1):121-7.
    View in: PubMed
    Score: 0.004
  281. Essential tremor quantification during activities of daily living. Parkinsonism Relat Disord. 2011 Aug; 17(7):537-42.
    View in: PubMed
    Score: 0.004
  282. Peripheral trauma and movement disorders: a systematic review of reported cases. J Neurol Neurosurg Psychiatry. 2011 Aug; 82(8):892-8.
    View in: PubMed
    Score: 0.004
  283. A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. Lancet Neurol. 2011 May; 10(5):415-23.
    View in: PubMed
    Score: 0.004
  284. Systematic genetic analysis of the PITX3 gene in patients with Parkinson disease. Mov Disord. 2011 Aug 01; 26(9):1729-32.
    View in: PubMed
    Score: 0.004
  285. Complement 3 and factor h in human cerebrospinal fluid in Parkinson's disease, Alzheimer's disease, and multiple-system atrophy. Am J Pathol. 2011 Apr; 178(4):1509-16.
    View in: PubMed
    Score: 0.004
  286. Cognitive outcome and reliable change indices two years following bilateral subthalamic nucleus deep brain stimulation. Parkinsonism Relat Disord. 2011 Jun; 17(5):321-7.
    View in: PubMed
    Score: 0.004
  287. Essential tremor: clinical correlates in 350 patients. Neurology. 1991 Feb; 41(2 ( Pt 1)):234-8.
    View in: PubMed
    Score: 0.004
  288. Dystonic tics in patients with Tourette's syndrome. Mov Disord. 1991; 6(3):248-52.
    View in: PubMed
    Score: 0.004
  289. Stiff-person syndrome: an autoimmune disease. Mov Disord. 1991; 6(1):12-20.
    View in: PubMed
    Score: 0.004
  290. CSF A?(42) and tau in Parkinson's disease with cognitive impairment. Mov Disord. 2010 Nov 15; 25(15):2682-5.
    View in: PubMed
    Score: 0.003
  291. Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol. 2010 Dec; 9(12):1164-1172.
    View in: PubMed
    Score: 0.003
  292. LINGO1 rs9652490 variant in Parkinson disease patients. Neurosci Lett. 2011 Jan 07; 487(2):174-6.
    View in: PubMed
    Score: 0.003
  293. Variable expression of Parkinson's disease: a base-line analysis of the DATATOP cohort. The Parkinson Study Group. Neurology. 1990 Oct; 40(10):1529-34.
    View in: PubMed
    Score: 0.003
  294. Tardive dyskinesia and other movement disorders secondary to aripiprazole. Mov Disord. 2011 Jan; 26(1):147-52.
    View in: PubMed
    Score: 0.003
  295. Botulinum toxin treatment of cranial-cervical dystonia, spasmodic dysphonia, other focal dystonias and hemifacial spasm. J Neurol Neurosurg Psychiatry. 1990 Aug; 53(8):633-9.
    View in: PubMed
    Score: 0.003
  296. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol. 2010 Jul; 68(1):18-27.
    View in: PubMed
    Score: 0.003
  297. Significance and confounders of peripheral DJ-1 and alpha-synuclein in Parkinson's disease. Neurosci Lett. 2010 Aug 09; 480(1):78-82.
    View in: PubMed
    Score: 0.003
  298. Neurologic approach to drug-induced movement disorders: a study of 125 patients. South Med J. 1990 May; 83(5):525-32.
    View in: PubMed
    Score: 0.003
  299. Multiple LRRK2 variants modulate risk of Parkinson disease: a Chinese multicenter study. Hum Mutat. 2010 May; 31(5):561-8.
    View in: PubMed
    Score: 0.003
  300. LINGO1 and LINGO2 variants are associated with essential tremor and Parkinson disease. Neurogenetics. 2010 Oct; 11(4):401-8.
    View in: PubMed
    Score: 0.003
  301. Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia. Parkinsonism Relat Disord. 2010 Jun; 16(5):316-23.
    View in: PubMed
    Score: 0.003
  302. DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain. 2010 Mar; 133(Pt 3):713-26.
    View in: PubMed
    Score: 0.003
  303. Botulinum toxin injections for cervical dystonia. Neurology. 1990 Feb; 40(2):277-80.
    View in: PubMed
    Score: 0.003
  304. Long-term deep brain stimulation for essential tremor: 12-year clinicopathologic follow-up. Mov Disord. 2010 Jan 30; 25(2):232-8.
    View in: PubMed
    Score: 0.003
  305. Progressive supranuclear palsy: motor, neurobehavioral, and neuro-ophthalmic findings. Adv Neurol. 1990; 53:293-304.
    View in: PubMed
    Score: 0.003
  306. Tardive oculogyric crises. Neurology. 1989 Nov; 39(11):1434-7.
    View in: PubMed
    Score: 0.003
  307. Metoclopramide-induced movement disorders. Clinical findings with a review of the literature. Arch Intern Med. 1989 Nov; 149(11):2486-92.
    View in: PubMed
    Score: 0.003
  308. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med. 2009 Sep 24; 361(13):1268-78.
    View in: PubMed
    Score: 0.003
  309. Occupation and risk of parkinsonism: a multicenter case-control study. Arch Neurol. 2009 Sep; 66(9):1106-13.
    View in: PubMed
    Score: 0.003
  310. Hemiballism-hemichorea. Clinical and pharmacologic findings in 21 patients. Arch Neurol. 1989 Aug; 46(8):862-7.
    View in: PubMed
    Score: 0.003
  311. The course of depressive symptoms in early Parkinson's disease. Mov Disord. 2009 Jul 15; 24(9):1306-11.
    View in: PubMed
    Score: 0.003
  312. Dystonia in musicians. Semin Neurol. 1989 Jun; 9(2):131-5.
    View in: PubMed
    Score: 0.003
  313. Lrrk2 R1441G-related Parkinson's disease: evidence of a common founding event in the seventh century in Northern Spain. Neurogenetics. 2009 Oct; 10(4):347-53.
    View in: PubMed
    Score: 0.003
  314. GIGYF2 Asn56Ser and Asn457Thr mutations in Parkinson disease patients. Neurosci Lett. 2009 May 01; 454(3):209-11.
    View in: PubMed
    Score: 0.003
  315. Lower body parkinsonism: evidence for vascular etiology. Mov Disord. 1989; 4(3):249-60.
    View in: PubMed
    Score: 0.003
  316. Coprophenomena in Tourette syndrome. Dev Med Child Neurol. 2009 Mar; 51(3):218-27.
    View in: PubMed
    Score: 0.003
  317. Dystonia and tremor induced by peripheral trauma: predisposing factors. J Neurol Neurosurg Psychiatry. 1988 Dec; 51(12):1512-9.
    View in: PubMed
    Score: 0.003
  318. A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristics. Mov Disord. 2008 Nov 15; 23(15):2194-201.
    View in: PubMed
    Score: 0.003
  319. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008 Nov 15; 23(15):2129-70.
    View in: PubMed
    Score: 0.003
  320. Neutralizing antibodies in dystonic patients who still respond well to botulinum toxin type A. Neurology. 2008 Sep 23; 71(13):1040; author reply 1040-1.
    View in: PubMed
    Score: 0.003
  321. Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay. Mov Disord. 2008 Jul 30; 23(10):1353-60.
    View in: PubMed
    Score: 0.003
  322. Five-year follow-up of unilateral posteroventral pallidotomy in Parkinson's disease. Surg Neurol. 2009 May; 71(5):551-8.
    View in: PubMed
    Score: 0.003
  323. Focal task-specific tremor and dystonia: categorization of occupational movement disorders. Neurology. 1988 Apr; 38(4):522-7.
    View in: PubMed
    Score: 0.003
  324. CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases. Am J Clin Pathol. 2008 Apr; 129(4):526-9.
    View in: PubMed
    Score: 0.003
  325. Depressed mood and memory impairment before and after unilateral posteroventral pallidotomy in Parkinson's disease. J Neuropsychiatry Clin Neurosci. 2008; 20(3):357-63.
    View in: PubMed
    Score: 0.003
  326. Case 3, 1988. Progressive myoclonic epilepsy, dementia, and blindness in a young girl. Mov Disord. 1988; 3(4):362-9.
    View in: PubMed
    Score: 0.003
  327. Rett syndrome: qualitative and quantitative differentiation from autism. J Child Neurol. 1988; 3 Suppl:S65-7.
    View in: PubMed
    Score: 0.003
  328. Cranial-cervical dyskinesias: an overview. Adv Neurol. 1988; 49:1-13.
    View in: PubMed
    Score: 0.003
  329. Etiology and differential diagnosis of blepharospasm and oromandibular dystonia. Adv Neurol. 1988; 49:103-16.
    View in: PubMed
    Score: 0.003
  330. Orofacial and other self-mutilations. Adv Neurol. 1988; 49:365-81.
    View in: PubMed
    Score: 0.003
  331. Blepharospasm and cranial-cervical dystonia (Meige's syndrome): familial occurrence. Adv Neurol. 1988; 49:117-23.
    View in: PubMed
    Score: 0.003
  332. Coexistent tardive dyskinesia and parkinsonism. Clin Neuropharmacol. 1987 Dec; 10(6):511-21.
    View in: PubMed
    Score: 0.003
  333. Potential outcome measures and trial design issues for multiple system atrophy. Mov Disord. 2007 Dec; 22(16):2371-7.
    View in: PubMed
    Score: 0.003
  334. Motor, behavioral and pharmacologic findings in Tourette's syndrome. Can J Neurol Sci. 1987 Aug; 14(3 Suppl):541-6.
    View in: PubMed
    Score: 0.003
  335. Short and long-term motor and cognitive outcome of staged bilateral pallidotomy: a retrospective analysis. Acta Neurochir (Wien). 2007; 149(9):857-66; discussion 866.
    View in: PubMed
    Score: 0.003
  336. The impact of depressive symptoms in early Parkinson disease. Neurology. 2007 Jul 24; 69(4):342-7.
    View in: PubMed
    Score: 0.003
  337. A founding LRRK2 haplotype shared by Tunisian, US, European and Middle Eastern families with Parkinson's disease. Parkinsonism Relat Disord. 2008; 14(1):77-80.
    View in: PubMed
    Score: 0.003
  338. G2019S mutation in the leucine-rich repeat kinase 2 gene is not associated with multiple system atrophy. Mov Disord. 2007 Mar 15; 22(4):546-9.
    View in: PubMed
    Score: 0.003
  339. Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology. 2007 Jan 23; 68(4):272-6.
    View in: PubMed
    Score: 0.003
  340. Tardive myoclonus. Mov Disord. 1987; 2(4):307-11.
    View in: PubMed
    Score: 0.003
  341. Blepharospasm and autoimmune diseases. Mov Disord. 1987; 2(3):159-63.
    View in: PubMed
    Score: 0.003
  342. Screening for Lrrk2 G2019S and clinical comparison of Tunisian and North American Caucasian Parkinson's disease families. Mov Disord. 2007 Jan; 22(1):55-61.
    View in: PubMed
    Score: 0.003
  343. Drug-induced dystonia in neuronal ceroid-lipofuscinosis. Pediatr Neurol. 1986 Jul-Aug; 2(4):236-7.
    View in: PubMed
    Score: 0.003
  344. Genomewide scans in North American families reveal genetic linkage of essential tremor to a region on chromosome 6p23. Brain. 2006 Sep; 129(Pt 9):2318-31.
    View in: PubMed
    Score: 0.003
  345. HS1-BP3 gene variant is common in familial essential tremor. Mov Disord. 2006 Mar; 21(3):306-9.
    View in: PubMed
    Score: 0.003
  346. Nurr1 in Parkinson's disease and related disorders. J Comp Neurol. 2006 Jan 20; 494(3):495-514.
    View in: PubMed
    Score: 0.002
  347. The phenomenology of tics. Mov Disord. 1986; 1(1):17-26.
    View in: PubMed
    Score: 0.002
  348. Parkinsonism and acquired hydrocephalus. Mov Disord. 1986; 1(1):59-64.
    View in: PubMed
    Score: 0.002
  349. Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study. Mov Disord. 2005 Jul; 20(7):783-91.
    View in: PubMed
    Score: 0.002
  350. Age-dependent dopaminergic dysfunction in Nurr1 knockout mice. Exp Neurol. 2005 Jan; 191(1):154-62.
    View in: PubMed
    Score: 0.002
  351. Examination of the SGCE gene in Tourette syndrome patients with obsessive-compulsive disorder. Mov Disord. 2004 Oct; 19(10):1237-8.
    View in: PubMed
    Score: 0.002
  352. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol. 2004 Jul; 61(7):1044-53.
    View in: PubMed
    Score: 0.002
  353. Apolipoprotein E controls the risk and age at onset of Parkinson disease. Neurology. 2004 Jun 08; 62(11):2005-9.
    View in: PubMed
    Score: 0.002
  354. Effects of visual and auditory cues on gait in individuals with Parkinson's disease. J Neurol Sci. 2004 Apr 15; 219(1-2):63-9.
    View in: PubMed
    Score: 0.002
  355. Clinical gait and balance scale (GABS): validation and utilization. J Neurol Sci. 2004 Jan 15; 217(1):89-99.
    View in: PubMed
    Score: 0.002
  356. Phenotypic features of Huntington's disease-like 2. Mov Disord. 2003 Dec; 18(12):1527-30.
    View in: PubMed
    Score: 0.002
  357. Glutathione S-transferase omega-1 modifies age-at-onset of Alzheimer disease and Parkinson disease. Hum Mol Genet. 2003 Dec 15; 12(24):3259-67.
    View in: PubMed
    Score: 0.002
  358. Treatment of hypophonia with collagen vocal cord augmentation in patients with parkinsonism. Mov Disord. 2003 Oct; 18(10):1190-2.
    View in: PubMed
    Score: 0.002
  359. Role of nitric oxide in rotenone-induced nigro-striatal injury. J Neurochem. 2003 Sep; 86(6):1338-45.
    View in: PubMed
    Score: 0.002
  360. Association study of Parkin gene polymorphisms with idiopathic Parkinson disease. Arch Neurol. 2003 Jul; 60(7):975-80.
    View in: PubMed
    Score: 0.002
  361. Haplotype analysis of the ETM2 locus in familial essential tremor. Neurogenetics. 2003 Aug; 4(4):185-9.
    View in: PubMed
    Score: 0.002
  362. Genetic polymorphisms of the N-acetyltransferase genes and risk of Parkinson's disease. Neurology. 2003 Apr 08; 60(7):1189-91.
    View in: PubMed
    Score: 0.002
  363. Mutations in NR4A2 associated with familial Parkinson disease. Nat Genet. 2003 Jan; 33(1):85-9.
    View in: PubMed
    Score: 0.002
  364. Association of homozygous 7048G7049 variant in the intron six of Nurr1 gene with Parkinson's disease. Neurology. 2002 Mar 26; 58(6):881-4.
    View in: PubMed
    Score: 0.002
  365. Intrafamilial phenotypic variability of the DYT1 dystonia: from asymptomatic TOR1A gene carrier status to dystonic storm. Mov Disord. 2002 Mar; 17(2):339-45.
    View in: PubMed
    Score: 0.002
  366. Association of single-nucleotide polymorphisms of the tau gene with late-onset Parkinson disease. JAMA. 2001 Nov 14; 286(18):2245-50.
    View in: PubMed
    Score: 0.002
  367. Identification of a high frequency of mutation at exon 8 of the ATP7B gene in a Chinese population with Wilson disease by fluorescent PCR. Arch Neurol. 2001 Nov; 58(11):1879-82.
    View in: PubMed
    Score: 0.002
  368. Thalamic deep brain stimulation: effects on the nontarget limbs. Mov Disord. 2001 Nov; 16(6):1137-42.
    View in: PubMed
    Score: 0.002
  369. Comparison of thalamotomy and pallidotomy for the treatment of dystonia. Neurosurgery. 2001 Apr; 48(4):818-24; discussion 824-6.
    View in: PubMed
    Score: 0.002
  370. Long-term efficacy of posteroventral pallidotomy in the treatment of Parkinson's disease. Neurology. 2000 Oct 24; 55(8):1218-22.
    View in: PubMed
    Score: 0.002
  371. Postural control in Parkinson's disease after unilateral posteroventral pallidotomy. Brain. 2000 Oct; 123 ( Pt 10):2141-9.
    View in: PubMed
    Score: 0.002
  372. Neuropsychological outcome after unilateral pallidotomy for the treatment of Parkinson's disease. J Neurol Neurosurg Psychiatry. 2000 Sep; 69(3):326-36.
    View in: PubMed
    Score: 0.002
  373. Variability and validity of polymorphism association studies in Parkinson's disease. Neurology. 2000 Aug 22; 55(4):533-8.
    View in: PubMed
    Score: 0.002
  374. Polymorphism of NACP-Rep1 in Parkinson's disease: an etiologic link with essential tremor? Neurology. 2000 Mar 14; 54(5):1195-8.
    View in: PubMed
    Score: 0.002
  375. Bruxism in Huntington's disease. Mov Disord. 2000 Jan; 15(1):171-3.
    View in: PubMed
    Score: 0.002
  376. Reduced Nurr1 expression increases the vulnerability of mesencephalic dopamine neurons to MPTP-induced injury. J Neurochem. 1999 Nov; 73(5):2218-21.
    View in: PubMed
    Score: 0.002
  377. The alpha-synuclein gene is not a major risk factor in familial Parkinson disease. Neurogenetics. 1999 Sep; 2(3):191-2.
    View in: PubMed
    Score: 0.002
  378. Comparison of mouse bioassay and immunoprecipitation assay for botulinum toxin antibodies. J Neurol Neurosurg Psychiatry. 1999 May; 66(5):612-6.
    View in: PubMed
    Score: 0.002
  379. The G209A mutation in the alpha-synuclein gene is not detected in familial cases of Parkinson disease in non-Greek and/or Italian populations. Arch Neurol. 1998 Dec; 55(12):1521-3.
    View in: PubMed
    Score: 0.002
  380. Posteroventral medial pallidotomy for treatment of Parkinson's disease: preoperative magnetic resonance imaging features and clinical outcome. J Neurosurg. 1998 Aug; 89(2):194-9.
    View in: PubMed
    Score: 0.001
  381. Accuracy of the clinical diagnoses of Lewy body disease, Parkinson disease, and dementia with Lewy bodies: a clinicopathologic study. Arch Neurol. 1998 Jul; 55(7):969-78.
    View in: PubMed
    Score: 0.001
  382. Pallidotomy for generalized dystonia. Mov Disord. 1998 Jul; 13(4):693-8.
    View in: PubMed
    Score: 0.001
  383. Assessment of motor function after stereotactic pallidotomy. Neurology. 1998 Jan; 50(1):266-70.
    View in: PubMed
    Score: 0.001
  384. Variability of the immunologic and clinical response in dystonic patients immunoresistant to botulinum toxin injections. Mov Disord. 1998 Jan; 13(1):150-4.
    View in: PubMed
    Score: 0.001
  385. Symptomatic and functional outcome of surgical treatment of cervical dystonia. J Neurol Neurosurg Psychiatry. 1997 Nov; 63(5):642-8.
    View in: PubMed
    Score: 0.001
  386. Microelectrode-guided posteroventral pallidotomy for treatment of Parkinson's disease: postoperative magnetic resonance imaging analysis. J Neurosurg. 1997 Sep; 87(3):358-67.
    View in: PubMed
    Score: 0.001
  387. Molecular detection of new mutations, resolution of ambiguous results and complex genetic counseling issues in Huntington disease. Am J Med Genet. 1996 Dec 18; 66(3):281-6.
    View in: PubMed
    Score: 0.001
  388. Ecstasy intoxication: an overlap between serotonin syndrome and neuroleptic malignant syndrome. Clin Neuropharmacol. 1996 Apr; 19(2):157-64.
    View in: PubMed
    Score: 0.001
  389. Neurologic presentation of Wilson disease without Kayser-Fleischer rings. Neurology. 1996 Apr; 46(4):1040-3.
    View in: PubMed
    Score: 0.001
  390. Neuropsychological functioning in cortical-basal ganglionic degeneration: Differentiation from Alzheimer's disease. Neurology. 1996 Mar; 46(3):720-6.
    View in: PubMed
    Score: 0.001
  391. Outcome after stereotactic thalamotomy for dystonia and hemiballismus. Neurosurgery. 1995 Mar; 36(3):501-7; discussion 507-8.
    View in: PubMed
    Score: 0.001
  392. Clozapine for acute and maintenance treatment of psychosis in Parkinson's disease. J Neuropsychiatry Clin Neurosci. 1995; 7(4):471-5.
    View in: PubMed
    Score: 0.001
  393. A comparison of postspace-flight orthostatic intolerance to vasovagal syncope and autonomic failure and the potential use of the alpha agonist midodrine for these conditions. J Clin Pharmacol. 1994 May; 34(5):466-71.
    View in: PubMed
    Score: 0.001
  394. Rett syndrome: controlled study of an oral opiate antagonist, naltrexone. Ann Neurol. 1994 Apr; 35(4):464-70.
    View in: PubMed
    Score: 0.001
  395. Blepharospasm-oromandibular dystonia associated with a left cerebellopontine angle meningioma. J Emerg Med. 1990 Sep-Oct; 8(5):571-4.
    View in: PubMed
    Score: 0.001
  396. Extrapyramidal involvement in Rett's syndrome. Neurology. 1990 Feb; 40(2):293-5.
    View in: PubMed
    Score: 0.001
  397. Rett syndrome and associated movement disorders. Mov Disord. 1990; 5(3):195-202.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.